ProCE Banner Activity

POLO: Randomized, Placebo-Controlled Phase III Trial of Maintenance Olaparib in Patients With Metastatic Pancreatic Cancer and Germline BRCA Mutation

Slideset Download
Conference Coverage
Maintenance therapy with olaparib improved PFS vs placebo in patients with metastatic pancreatic cancer and germline BRCA mutations who had not progressed with platinum-based chemotherapy.

Released: June 06, 2019

Expiration: June 04, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro